Zeev Bronfeld (Interim Chairman)
David Aviezer (President and CEO)
$11.51 million (2013)
$113.33 million (2013)
Number of employees
Footnotes / references
Protalix BioTherapeutics is an Israeli pharmaceutical company whose plant-based enzyme, taliglucerase alfa, has been approved by the U.S. Food and Drug Administration for the treatment of Gaucher disease.